Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

Gene-editing company raises €56M in Series A2 to advance gene-editing therapies for curing heart disease

Shubham Sharma by Shubham Sharma
June 15, 2020
in News, (Crowd)funding, Health & Medtech, Startups
0
Gene-editing company raises €56M in Series A2 to advance gene-editing therapies for curing heart disease
48
SHARES
LinkedInTwitterWhatsAppFacebook

Gene editing is a type of genetic engineering and it is a relatively newer concept. It involves insertion, deletion, modification or replacement of DNA in a living organism’s genome. Gene editing could be a powerful tool for helping people suffering from chronic ailments. Some companies are working tirelessly to employ gene editing for solving health problems and Cambridge, Massachusetts based Verve Therapeutics is one of them. The company has now secured €56M in Series A2 to advance gene-editing therapies for reducing the risk of coronary heart disease. 

Series A2 brings in €56M for research and development 

The latest series A2 round for Verve Therapeutics was led by company’s existing investor GV, which was formerly known as Google Ventures. Furthermore, current investors ARCH Venture Partners, F-Prime Capital, and Biomatics Capital also joined the investment round. New investors Wellington Management and Casdin Capital also joined in. With the latest funding, the overall funds raised by the company touch a total of €109.5 million.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

Coronary heart disease is said to be one of the leading causes of death in the U.S. and worldwide. Verve capital is developing a solution to tackle the issue and lower its risks in adults. It is doing so by developing one-time, gene-editing therapies that can safely edit targeted genes in the liver, which will result in permanent lowering of LDL cholesterol and triglycerides, which are key risk factors causing coronary heart disease. With the freshly acquired funds, the company will focus on advancing its lead program through IND-enabling studies and progress follow-on pipeline programs.

“We are immensely grateful to our existing investors for their continued support and commitment to our bold vision to eradicate coronary heart disease, and are very pleased to welcome Wellington Management and Casdin Capital to our investor syndicate,” says Sekar Kathiresan, M.D, co-founder and CEO of Verve. “This financing is a testament to the tremendous work by the Verve team and will position us to rapidly advance our lead therapeutic candidate through IND-enabling studies and expand our pipeline of development programs. People with heart disease are in urgent need of new therapeutic options, and Verve’s research to date further underscores the transformative potential of gene editing as a therapeutic approach for these patients.”

Image credits: Verve Therapeutics

Stay tuned to Silicon Canals for more European technology news

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Nebula CTO Andre Witte
Cloud spend management 😱
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the...Show More
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the costs at bay in 2021. Show Less
Read more
Tags: featuredmedtechnews
Share3Tweet11SendShare21

Featured events

07apr10:0012:30FeaturedWorkshop: pr for startupsHow to grow your startup with the help of public relations

Partner content | Work with us

Future Hamburg Award: Looking for the best startups to forge the city of the future

The Humblebrag launches online course to help emerging leaders amplify their visibility and voice

Blue Tulip Awards announce 5 finalists in the Food & Water and Education & Employment theme

Impact media foundation 5 Media offers grants up to €100,000 per year to drive a sustainable future

Here’s how cryptocurrency will take over the world

Breaking news from Amsterdam | Partner

Amsterdam-based Founda Health raises €12.3M to build infrastructure for global healthcare sector; here’s how

Combining financial with human capital in Amsterdam: Volta, LevelUp and Tech Rise on their approach

Here’s why Just Eat Takeaway is expanding its offices in Amsterdam

Amsterdam-based Veylinx uses Nobel Prize-winning approach to solve the problem of unreliable survey data; raises €1.6M

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info